Immunosuppression and BAL neutrophilia in asthma

Yoshiro Tanizaki, Hikaru Kitani, Takashi Mifune, Fumihiro Mitsunobu, Kazuhiro Kajimoto, Keisuke Sugimoto, Satoshi Yokota, Junichi Hiramatsu, Masashi Kawaraya, Hideo Harada and Ikuro Kimura

Division of Medicine, Misasa Medical Branch, Department of Laboratory Medicine, Second Department of Medicine, Okayama University Medical School

Abstract: Cellular composition of bronchoalveolar lavage (BAL) fluid was compared between two age-matched steroid-dependent intractable asthma (SDIA) groups: 17 group A patients (serum IgG level < 1000 mg/dl) whose immunity was regarded as being suppressed by long-term glucocorticoid therapy and 17 group B patients (serum IgG level > 1200 mg/dl). 1. The levels of serum IgA and IgM were significantly decreased in group A compared to the levels in group B patients. 2. The number of blood lymphocytes was also significantly lower in group A than in group B patients. However, the number of blood neutrophils was not different between the two asthma groups. 3. The number of BAL lymphocytes was significantly lower in group A than in group B patients. 4. BAL neutrophilia (more than $1.5 \times 10^4 / ml$) was observed in 6 of the 17 (35.3%) patients in group A, but not observed in any patients in group B. The number of BAL neutrophils was significantly greater in group A than in group B patients.

These results suggest that there is a correlation between immunosuppression by glucocorticoids and BAL neutrophilia in patients with bronchial asthma.

Key words: immunosuppression, BAL neutrophilia, glucocorticoids, bronchial asthma

Introduction

Recent studies on analysis of cellular and humoral events in bronchoalveolar (BAL) fluid have demonstrated that airway inflammation is a common feature of bronchial asthma (1–5). Airway inflammation which consists of inflammatory cells such as lymphocytes (6–8), neutrophils (9), eosinophils (10, 11), and basophils, is related to
the severity of asthma (12).

Asthma is classified into three clinical types according to symptoms and signs: Ia. simple bronchoconstriction type, Ib. bronchoconstriction + hypersecretion type, and II bronchial obstruction type (13–15). Of these three asthma types, type II asthma is characterized by an increased number of bronchoalveolar neutrophils and marked decrease in the values of ventilatory parameters. An increased number of BAL neutrophils is sometimes observed in asthmatic patients with long-term glucocorticoid therapy (16). These findings suggest that there is a correlation between long-term glucocorticoid therapy and an increased number of BAL neutrophils in patients with bronchial asthma.

Long-term glucocorticoid regimen brings about many side effects such as hypertension, diabetes mellitus, osteoporosis, muscle weakness, suppression of adrenocortical glands and suppression of humoral and cellular immunity. Of these side effects, immunosuppression by glucocorticoids may affect inflammatory process in the airways of asthma and be related to asthma severity.

In the present study, a correlation between immunosuppression by glucocorticoids and BAL neutrophilia was examined in patients with steroid-dependent intractable asthma (SDIA).

**Subjects and Methods**

The subjects of this study were 34 patients with bronchial asthma (17 females and 17 males, mean 53.0 years, range 21–71 years). The mean level of serum IgE was 428 IU/ml (range 11–3058 IU/ml). All the subjects were non-smokers, and they were regarded as having steroid-dependent intractable asthma (SDIA), since they had been treated with glucocorticoids for more than 2 years. The subjects were divided into two groups according to the level of serum IgG: less than 1000 mg/dl (group A) and more than 1200 mg/dl (group B). The patients in group A were regarded as their immunity being suppressed by glucocorticoids, and in group B patients the immunity was not suppressed.

Bronchoalveolar lavage (BAL) was performed after informed consent was obtained from all the subjects. The BAL was carried out in all study subjects by a previously reported method (14, 15) when their attacks were atable with prednisolone of 5 mg/day or less. Briefly, the aspirates were centrifuged at 1200 rpm for 10 min at 4°C after filtration through a sterile steel mesh, and the resultant cell pellet was resuspended in Tris ACM. After total cell number was counted, smear preparations made with the cell suspensions were stained with May Giemsa. A differential cell count was performed on 500 cells, excluding epithelial cells. In the present study, the mean recovery rate at BAL was 26.5±11.4% (±SD), and the total cell number was 7.0±3.0×10^6. The results were expressed as /ml.

The levels of serum IgG, IgA, and IgM were measured by turbidometric immunoassay. Serum IgE level was estimated by radioimmunosorbest test (RIST).

**Results**

Table 1 shows characteristics of patients with bronchial asthma divided by the level of serum IgG. In this study, 17 patients whose immunity was suppressed by long-term glucocorticoid therapy were at first selected, and then 17 age-matched asthma patients whose serum IgG level was more than 1200 mg/dl (regarded as not being suppressed by
Immunosuppression and BAL neutrophilia in asthma

Glucocorticoids (e.g., prednisolone, methylprednisolone, or dexamethasone) were selected. Thus, the mean age in the two groups was almost the same. Serum IgE level was higher in patients of group B than in those of group A, although this difference was not significant. The levels of serum IgA and IgM were significantly lower in patients of group A than in those of group B (IgA: p<0.02; IgM: p<0.01). Distribution of serum IgG levels in groups A and B was shown in Fig. 1.

Table 1. Characteristics of patients with bronchial asthma studied

<table>
<thead>
<tr>
<th>Asthma group</th>
<th>No of patients</th>
<th>Age (yr)</th>
<th>Serum levels of IgE (IU/ml)</th>
<th>IgG (mg/dl)</th>
<th>IgA (mg/dl)</th>
<th>IgM (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>17</td>
<td>52.9</td>
<td>306</td>
<td>194^a</td>
<td>136^b</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>±356</td>
<td>±118</td>
<td>±45</td>
<td>±104</td>
</tr>
<tr>
<td>B</td>
<td>17</td>
<td>53.1</td>
<td>533</td>
<td>1402</td>
<td>246^a</td>
<td>224^b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>±733</td>
<td>±539</td>
<td>±53</td>
<td>±67</td>
</tr>
</tbody>
</table>

Group A: patients with serum IgG level of less than 1000 mg/dl. B: patients with serum IgG level of less than 1200 mg/dl. *p<0.02; **p<0.01.

Immunosuppressive action of glucocorticoids can be observed in serum immunoglobulin concentrations and blood cell count in peripheral blood. The number of blood neutrophils was not different between groups A (4808±1286/cmm) and B (4576±1419/cmm), as shown in Fig. 2. The number of blood lymphocytes was significantly decreased in group A patients (serum IgG level less than 1000 mg/dl) compared to that in group B patients (p<0.01) (Fig. 3).

Table 2 shows the results of BAL examinations. Total cell number and recovery rate at BAL were slightly greater in group B than in group A subjects, although this was not significant.

The number of BAL macrophages was not significantly different between groups A and B (Fig. 4). The number of BAL lymphocytes was decreased in group A patients, which was

![Fig. 1. Serum IgG levels in patients with bronchial asthma. Group A: patients with serum IgG level of less than 1000 mg/dl; B: patients with serum IgG level of more than 1200 mg/dl.](image1)

![Fig. 2. Number of blood neutrophils in patients with bronchial asthma. Group A: patients with serum IgG level of less than 1000 mg/dl; B: patients with serum IgG level of more than 1200 mg/dl.](image2)
significantly lower than that in group B patients (P<0.05) (Fig. 5). BAL neutrophilia (more than $1.5 \times 10^4/\text{ml}$) was observed in 6 of the 17 (35.3%) patients in group A, but in none of them in group B. The mean number of BAL neutrophils was significantly greater in group A than in group B patients (p<0.05) (Fig. 6, Table 2).

![Fig. 3. Number of blood lymphocytes in patients with bronchial asthma. Group A: patients with serum IgG level of less than 1000 mg/dl; group B: patients with serum IgG level of more than 1200 mg/dl. *p < 0.01.](image)

**Table 2. BAL examination results in patients with bronchial asthma studied**

<table>
<thead>
<tr>
<th>Asthma group</th>
<th>Recovery rate</th>
<th>Total cell number (x10^6)</th>
<th>BAL cells (x10^4/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mac</td>
<td>Lym</td>
</tr>
<tr>
<td>A</td>
<td>24.7 ± 10.1</td>
<td>11.8 ± 2.8</td>
<td>1.24 ± 1.18</td>
</tr>
<tr>
<td>B</td>
<td>20.4 ± 12.2</td>
<td>18.9 ± 3.1</td>
<td>3.13 ± 1.66</td>
</tr>
</tbody>
</table>

Group A: patients with serum IgG level of less than 1000 mg/dl; group B: patients with serum IgG level of more than 1200 mg/dl. a:p < 0.001; b:p < 0.05.

![Fig. 4. Number of BAL macrophages in patients with bronchial asthma. Group A: patients with serum IgG level of less than 1000 mg/dl; group B: patients with serum IgG level of more than 1200 mg/dl.](image)

![Fig. 5. Number of BAL lymphocytes in patients with bronchial asthma. Group A: patients with serum IgG level of less than 1000 mg/dl; group B: patients with serum IgG level of more than 1200 mg/dl. *p < 0.001.](image)
Despite many kinds of newly developed antiasthma agents, there are some patients with bronchial asthma whose attacks can not be controlled with conventional antiasthma drugs except glucocorticoids. They often require long-term glucocorticoid therapy to control asthma attacks. Long-term glucocorticoid therapy for bronchial asthma brings about many side effects. Of these side effects, suppression of adrenocortical glands and suppressed immunity by glucocorticoids may affect the pathogenesis of asthma.

There is increasing evidence that airway inflammation in bronchial asthma play an important role in the pathogenesis of the disease (1-5). The roles of inflammatory cells such as lymphocytes (6-8), neutrophils (9), eosinophils (10, 11), and basophils, which migrate from bloodstream, have been extensively studied in patients with asthma. It has been reported that numbers of activated T-lymphocytes and eosinophils in BAL fluid are increased in asthma attacks compared to healthy subjects (12). Long-term glucocorticoid therapy may affect these inflammatory cells in patients with asthma.

In the present study, cellular composition of bronchoalveolar lavage (BAL) fluid was examined in relation to suppressed immunity by glucocorticoids. Two asthma groups, group A whose immunity was suppressed by glucocorticoids, as expressed by low serum IgG level (less than 1000 mg/dl), and group B whose immunity was not suppressed, consisted of each 17 patient group with steroid-dependent intractable asthma (SDIA). In group A patients (with suppressed immunity), decreased levels of IgG, IgA, and IgM, and decreased numbers of blood and BAL lymphocytes were observed compared to the numbers in group B patients (without suppressed immunity). These results show that serum levels of immunoglobulins, IgG, IgA, and IgM, and decreased numbers of blood and BAL lymphocytes tend to decrease in some patients with asthma by long-term glucocorticoid therapy.

BAL neutrophilia (more than 1.5x10⁴/mℓ) was observed in 6 of the 17 (35.3%) patients with suppressed immunity, but in none of them without suppressed immunity. Moreover, the number of BAL neutrophils was significantly greater in group A than in group B patients. The results suggest that long-term glucocorticoid therapy brings about suppressed immunity as expressed by decreased levels of serum IgG, IgA, and IgM, and decreased numbers of blood and BAL

Fig. 6. Number of BAL neutrophils in patients with bronchial asthma. Group A: patients with serum IgG level of less than 1000 mg/dl; group B: patients with serum IgG level of more than 1200 mg/dl. *p < 0.05.

Discussion
lymphocytes, and in such patients with suppressed immunity BAL neutrophilia is often observed. In these conditions, asthma is severe and difficult to control.

References


気管支喘息における副腎皮質ホルモン長期投与による免疫抑制と気管支肺胞洗浄液中好中球増多との関連

谷崎勝朗, 貴谷 光, 御船尚志, 光延文裕, 梶本和宏, 杉本啓介, 橋田 聡, 平松陸一, 五屋正志, 原田英雄1), 木村郁郎2)

岡山大学医学部附属三朝病院内科, 1)医学部臨床検査医学, 2)医学部第2内科

ステロイド依存性重症難治性喘息を, 免疫抑制の見られる症例（血清IgG値 1000 mg/dl 以下）（グループA）と抑制の見られない症例（血清IgG値 1200 mg/dl 以上）（グループB）の2群に分け, 気管支肺胞洗浄液中の細胞成分について比較検討した。

1. 血清IgAおよびIgM値は, グループBに比べ免疫抑制の見られるグループAにおいて有意に低い値であった。